Next Article in Journal
Predictive Power of In Silico Approach to Evaluate Chemicals against M. tuberculosis: A Systematic Review
Previous Article in Journal
The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression
Previous Article in Special Issue
Novel 11-Substituted Ellipticines as Potent Anticancer Agents with Divergent Activity against Cancer Cells
Open AccessEditorial

Special Issue “Anticancer Drugs”

School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Trinity Biomedical Sciences Institute, 152-160 Pearse Street, 2 DO2R590 Dublin, Ireland
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(3), 134; https://doi.org/10.3390/ph12030134
Received: 6 September 2019 / Accepted: 6 September 2019 / Published: 16 September 2019
(This article belongs to the Special Issue Anticancer Drugs)
The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. This Special Issue also provides an understanding of the biologic and genotypic context in which targets are selected for oncology drug discovery, thus providing a rationalization for the biological activity of these drugs and guiding the design of more effective agents. In this Special Issue of Pharmaceuticals dedicated to anticancer drugs, we present a selection of preclinical research papers including both traditional chemotherapeutic agents and newer more targeted therapies and biological agents. We have included articles that report the design of small molecules with promising anticancer activity as tubulin inhibitors, vascular targeting agents, and topoisomerase targeting agents, alongside a comprehensive review of clinically successful antibody-drug conjugates used in cancer treatment. View Full-Text
Keywords: snticancer drugs; cancer drug design; cancer immunotherapy; conjugate and hybrid drugs, cisplatin resistance, topoisomerase inhibitors; microtubule targeted drugs snticancer drugs; cancer drug design; cancer immunotherapy; conjugate and hybrid drugs, cisplatin resistance, topoisomerase inhibitors; microtubule targeted drugs
MDPI and ACS Style

Meegan, M.J.; O’Boyle, N.M. Special Issue “Anticancer Drugs”. Pharmaceuticals 2019, 12, 134.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop